# Genetic Determinants of Coronary Artery Disease in Type 2 Diabetes Mellitus Among Asian Populations: A Meta-Analysis

**Authors:** Aida Kabibulatova, Kamilla Mussina, Joseph Almazan, Antonio Sarria-Santamera, Alessandro Salustri, Kuralay Atageldiyeva

PMC · DOI: 10.3390/medsci14010052 · Medical Sciences · 2026-01-21

## TL;DR

This study identifies specific genes linked to heart disease risk in Asian patients with type 2 diabetes, highlighting the need for population-specific genetic research.

## Contribution

The first meta-analysis focusing on genetic variants associated with coronary artery disease in Asian populations with type 2 diabetes.

## Key findings

- The PCSK1, GLP1R, and ADIPOQ genes were associated with increased coronary artery disease risk in Asian T2DM patients.
- The ACE and Q192R genes showed possible protective effects against coronary artery disease.
- High heterogeneity suggests complex and population-specific genetic factors influencing CAD risk in this group.

## Abstract

Background/Objectives: Type 2 diabetes mellitus (T2DM) significantly elevates the risk of coronary artery disease (CAD), particularly in Asian populations where both conditions are epidemic. While shared genetic factors contribute to this comorbidity, evidence from Asian cohorts remains fragmented, with limited focus on population-specific variants. This meta-analysis synthesizes evidence on genetic variants associated with CAD risk in Asian patients with T2DM. Methods: We systematically searched several databases according to the PRISMA statement and checklist. Pooled odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were calculated using random-effects models, with heterogeneity assessed via I2 and Cochran’s Q, and publication bias via funnel plots and Egger’s test. Results: In total, data on 11,268 subjects were reviewed, including 4668 cases and 6600 controls. Among 950 identified studies, 18 met eligibility criteria, and 14 studies provided sufficient data for the meta-analysis. The random-effects pooled estimate across all studied variants was not statistically significant (OR = 1.16 [95% CI: 0.68–2.00]; z = 0.56, p = 0.58). However, analysis of individual loci revealed gene-specific associations with CAD among this population: PCSK1 gene (OR = 2.12 [95% CI: 1.26–3.52]; p < 0.05; weight = 8.77%), GLP1R gene (OR = 2.25 [95% CI: 1.27–3.97]; p < 0.01; weight = 8.62%). ADIPOQ gene (OR = 8.00 [95% CI: 2.34–27.14]; p < 0.01; weight = 6.35%). Several genes were associated with an elevated risk of CAD: PCSK1 gene (OR = 2.12 [95% CI: 1.26–3.52]; p < 0.05; weight = 8.77%), GLP1R gene (OR = 2.25 [95% CI: 1.27–3.97]; p < 0.01; weight = 8.62%) and ADIPOQ gene (OR = 8.00 [95% CI: 2.34–27.14]; p < 0.01; weight = 6.35%). Several genes were associated with possible protective effects: ACE gene (OR = 0.41 [95% CI: 0.23–0.73]; p < 0.01; weight = 8.57%), Q192R gene (OR = 0.20 [95% CI: 0.08–0.52]; p < 0.001; weight = 7.41%). Heterogeneity was substantial (τ2 = 0.78; I2 = 81.95%; Q (13) = 64.67, p < 0.001). Conclusions: This first meta-analysis of genetic variants associated with CAD in Asian populations with T2DM identified specific locus-level associations implicating lipid metabolism, incretin signaling, and oxidative stress pathways. The lack of a significant pooled effect, alongside high heterogeneity, underscores the complexity and population-specific nature of this genetic architecture. These findings suggest that effective precision risk stratification may depend more on specific variants than on a broad polygenic signal, highlighting the need for further research in a larger, distinct sample size.

## Linked entities

- **Genes:** PCSK1 (proprotein convertase subtilisin/kexin type 1) [NCBI Gene 5122], GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740], ADIPOQ (adiponectin, C1Q and collagen domain containing) [NCBI Gene 9370], ACE (angiotensin I converting enzyme) [NCBI Gene 1636]
- **Diseases:** coronary artery disease (MONDO:0005010), type 2 diabetes mellitus (MONDO:0005148)

## Full-text entities

- **Genes:** INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, AGT (angiotensinogen) [NCBI Gene 183] {aka ANHU, SERPINA8, hFLT1}, GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}, STK11 (serine/threonine kinase 11) [NCBI Gene 6794] {aka LKB1, PJS, hLKB1}, FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}, PSRC1 (proline and serine rich coiled-coil 1) [NCBI Gene 84722] {aka DDA3, FP3214}, CELSR2 (cadherin EGF LAG seven-pass G-type receptor 2) [NCBI Gene 1952] {aka ADGRC2, CDHF10, EGFL2, Flamingo1, MEGF3}, APOB (apolipoprotein B) [NCBI Gene 338] {aka FCHL2, FLDB, LDLCQ4, apoB-100, apoB-48}, PCSK9 (proprotein convertase subtilisin/kexin type 9) [NCBI Gene 255738] {aka FH3, FHCL3, HCHOLA3, LDLCQ1, NARC-1, NARC1}, ADIPOQ (adiponectin, C1Q and collagen domain containing) [NCBI Gene 9370] {aka ACDC, ACRP30, ADIPQTL1, ADPN, APM-1, APM1}, GIP (gastric inhibitory polypeptide) [NCBI Gene 2695], SIRT1 (sirtuin 1) [NCBI Gene 23411] {aka SIR2, SIR2L1, SIR2alpha}, SERPINE1 (serpin family E member 1) [NCBI Gene 5054] {aka PAI, PAI-1, PAI1, PLANH1}, VWF (von Willebrand factor) [NCBI Gene 7450] {aka F8VWF, VWD}, APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}, CNR1 (cannabinoid receptor 1) [NCBI Gene 1268] {aka CANN6, CB-R, CB1, CB1A, CB1K5, CB1R}, LDLR (low density lipoprotein receptor) [NCBI Gene 3949] {aka LDLCQ2}, PCSK1 (proprotein convertase subtilisin/kexin type 1) [NCBI Gene 5122] {aka BMIQ12, NEC1, PC1, PC1/3, PC3, SPC3}, PLXDC2 (plexin domain containing 2) [NCBI Gene 84898] {aka PLXDC2-OT, TEM7R}, AP2B1 (adaptor related protein complex 2 subunit beta 1) [NCBI Gene 163] {aka ADTB2, AP105B, AP2-BETA, CLAPB1}, PON1 (paraoxonase 1) [NCBI Gene 5444] {aka ESA, MVCD5, PON}
- **Diseases:** Diabetes (MESH:D003920), myocardial infarction (MESH:D009203), cardiovascular disease (MESH:D002318), insulin resistance (MESH:D007333), familial hypercholesterolemia (MESH:D006938), hyperglycemia (MESH:D006943), thrombosis (MESH:D013927), injury to (MESH:D014947), Disease (MESH:D004194), inflammation (MESH:D007249), acute coronary syndromes (MESH:D054058), atherogenesis (MESH:D050197), coronary complications (MESH:D003327), AGEs (MESH:D003643), stenosis (MESH:D003251), inherited autosomal dominant disorder (MESH:D030342), coronary stenosis (MESH:D023921), hypercholesterolemia (MESH:D006937), T2DM (MESH:D003924), CAD (MESH:D003324), stroke (MESH:D020521), non-communicable (MESH:D000073296)
- **Chemicals:** carbohydrate (MESH:D002241), triglycerides (MESH:D014280), sugars (MESH:D000073893), glucose (MESH:D005947), nitric oxide (MESH:D009569), lipid (MESH:D008055)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** 276G/T, rs16924934, rs3811951, rs4646994, G1359A, rs12219125, rs2010963, rs2241766, rs2794521, Q192R, rs4714210, rs12977689, rs429358, rs599839, Q192R, rs8078510, rs266729

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12922016/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12922016/full.md

## References

90 references — full list in the complete paper: https://tomesphere.com/paper/PMC12922016/full.md

---
Source: https://tomesphere.com/paper/PMC12922016